Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 219 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The open-house model is not subject to procurement law; potential legal uncertainty regarding contract stability.

No indication of discount rates or market size; profitability depends on negotiated discounts and volume.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Provision of Certolizumab pegol (ATC L04AB05) under a discount agreement with AOK Bayern
  • Agreement to a fixed discount model; terms are predefined and non-negotiable
Afficher le résumé complet

This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive discount agreements on the pharmaceutical active substance Certolizumab pegol (ATC L04AB05). Any interested pharmaceutical company that meets the eligibility criteria can join. The contract duration is from 01.06.2025 to 31.05.2027. No estimated value is provided. Submission can be in paper form or electronically with a qualified electronic signature. The contract is automatically terminated if a regular procurement discount agreement for the same substance comes into effect.

Risques

The open-house model is not subject to procurement law; potential legal uncertainty regarding contract stability.

No indication of discount rates or market size; profitability depends on negotiated discounts and volume.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer)

Administrative

  • Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submit signed contract and attachment specifying the medicinal products

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; this is an open-house model with no selection.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05

Non-exclusive discount agreements for Certolizumab pegol. Open to all qualified pharmaceutical companies. Contracts are identical and non-negotiable.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; this is an open-house model with no selection.

Date limite

Deadline Apr 05, 2027

Détails de la procédure

Date de publication
15 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
246855-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30